Erythropoietin-induced Hypertension in Chronic Kidney Disease—A Mechanistic Randomized Controlled Trial
American Journal of Hypertension · 2026
DOI: 10.1093/ajh/hpaf200 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hypertension, 2026. Verfasst von Rajiv Agarwal. Beteiligte Einrichtung: Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Hypertension, Darbepoetin alfa, Hematinics. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: US Veterans administration.
Abstract (Originalsprache)
Background
The mechanism of hypertension associated with erythropoiesis-stimulating agents in chronic kidney disease (CKD) is complex and remains poorly understood.
Methods
Here, anemic hypertensive patients with CKD and well-controlled or mildly elevated BP as confirmed by 24-hour ABP monitoring were randomly assigned to either a waitlisted group or darbepoetin in a 1:1 ratio stratified by stages of albuminuria. The primary end point was the change in 24-hour diastolic ABP from baseline to 12 weeks.
Results
We screened 1699 patients and randomized 27 patients of the planned 160. Mean age (SD) was 75 (8) years, mean hemoglobin 9.4 (0.6) g/dL, mean clinic BP 124.4 (19.5)/57.2 (11.4) mm Hg and was similar between groups. At 12 weeks there was 1.7 g/dL (95% CI, 0.9-2.5 g/dL) difference in hemoglobin between waitlisted and immediate start group. Within group change in diastolic 24-hour ABP in the waitlisted group was −1.91 mm Hg and the immediate start group was +1.07 mm Hg. The difference in the changes was 2.98 mm Hg (95% CI, −1.36 to 7.31), P = .18. Comparing SBP, endothelial function, and UACR in the waitlisted and immediate start groups showed no significant differences between groups. However, within the waitlisted group UACR increased 35% from baseline (95% CI, 11%-82%) with darbepoetin exposure. Cardiovascular and atherothrombotic serious adverse events were more frequent during darbepoetin exposure.
Conclusions
Among anemic CKD patients with reasonably controlled hypertension, exposure to darbepoetin did not change 24-hour ABP or endothelial function. However, increase in albuminuria and serious adverse events during exposure to darbepoetin is a cause for concern and requires larger studies to affirm or refute these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, IN, United States.
ORCID-Profile: Rajiv Agarwal
Förderung
- US Veterans administration
Zitieren
APA
Agarwal, R. (2026). Erythropoietin-induced Hypertension in Chronic Kidney Disease—A Mechanistic Randomized Controlled Trial. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf200
Vancouver
Agarwal R. Erythropoietin-induced Hypertension in Chronic Kidney Disease—A Mechanistic Randomized Controlled Trial. American Journal of Hypertension. 2026. doi:10.1093/ajh/hpaf200
BibTeX
@article{Agarwal2026,
author = {Agarwal, Rajiv},
title = {Erythropoietin-induced Hypertension in Chronic Kidney Disease—A Mechanistic Randomized Controlled Trial},
journal = {American Journal of Hypertension},
year = {2026},
doi = {10.1093/ajh/hpaf200}
}
EUVIMED